Start Over

Myoinositol in Autoimmune Thyroiditis.

Authors :: Paparo SR
Ferrari SM
Patrizio A
Elia G
Ragusa F
Botrini C
Balestri E
Guarneri F
Benvenga S
Antonelli A
Fallahi P
Source :: Frontiers in endocrinology [Front Endocrinol (Lausanne)] 2022 Jun 28; Vol. 13, pp. 930756. Date of Electronic Publication: 2022 Jun 28 (Print Publication: 2022).
Publication Year :: 2022
Abstract: Myoinositol (Myo) is an isoform of inositol, a cyclic polyol with 6 hydroxyl groups. Myo is mainly derived from dietary intake while its endogenous production is generated from glucose by enzymatic reactions. Moreover, Myo is also synthesized de novo by catabolism of phosphatidylinositol (PI), phosphoinositides (PIP), and inositol phosphates (IP). Myo has a determinant role in thyroid function and autoimmune diseases as it regulates iodine organification and thyroid hormone biosynthesis by the formation of hydrogen peroxide (H <subscript>2</subscript> O <subscript>2</subscript> ) in thyrocytes. Depletion of Myo that is involved in the thyroid stimulating hormone (TSH) signaling pathway, may cause the development of thyroid diseases such as hypothyroidism. TSH levels significantly decreased in patients with subclinical hypothyroidism, with or without autoimmune thyroiditis, after treatment with Myo plus Selenium (Myo+Se). In addition to TSH, antithyroid autoantibodies are reduced. This review summarizes the role of Myo in the thyroidal physiology and its role in the management of some thyroid diseases.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Paparo, Ferrari, Patrizio, Elia, Ragusa, Botrini, Balestri, Guarneri, Benvenga, Antonelli and Fallahi.)